Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

For years, inflammatory bowel disease research focused on a single idea: find the bad bacteria. Sequence the gut, see who has changed, and build a suspect list. And that list grew. Studies reported depleted Firmicutes, enriched Proteobacteria, and reduced Faecalibacterium prausnitzii. Consistent patterns emerged, replicated across laboratories. But here's the problem: knowing who is present tells you almost nothing about what they are doing. The gut microbiome encodes more than one hundred times the number of genes in the human genome. A community can shift its metabolic output dramatically while its membership barely changes. Morgan and colleagues suspected the field had been cataloguing shadows. Their study was built to look at the source of light. Morgan and colleagues analyzed two hundred thirty-one subjects across two clinical cohorts: the Ocean State Crohn's and Colitis Area Registry, known as OSCCAR, and the Prospective Registry in Inflammatory Bowel Disease Study at Massachusetts General Hospital, called PRISM. The group included one hundred twenty-one Crohn's disease patients, seventy-five with ulcerative colitis, and twenty-seven healthy controls, with samples drawn from both stool and intestinal biopsies. Ulcerative colitis is confined to the colon, while Crohn's disease can affect any part of the digestive tract, including the ileum, which is the lower small intestine. That anatomical distinction will matter later. The sequencing approach used was sixteen S ribosomal RNA gene pyrosequencing — a method that amplifies a specific, highly conserved stretch of bacterial DNA to identify which organisms are present. After quality filtering, reads averaged two thousand eight hundred sixty per sample. That tells you composition. To get at function, the team took an additional step: they mapped detected microbial phylotypes onto a reference phylogeny annotated with over one thousand known bacterial genomes, then used those genomes' gene content to infer what metabolic pathways the community was likely using. Think of it as asking: given the relatives of these microbes and what their relatives are known to do, what is this community probably capable of? Those inferred functional profiles were then run through a tool called HUMAnN to reconstruct metabolic modules and pathways. Crucially, eleven samples — seven healthy controls and four Crohn's patients — underwent full shotgun metagenomic sequencing, reading the actual functional genes directly, to check whether the inferences held up. Six of seven highlighted metabolic modules preserved the same directional trend predicted from the sixteen S inference. The approach worked. The other methodological move that made the findings credible was statistical. To separate disease effects from everything else — age, smoking, sample type, and medications — the team used a sparse multivariate linear modeling framework. Metadata candidates were first selected by boosting and then tested in generalized linear models with false discovery rate control. This matters because, in clinical cohorts, the microbiome is not just shaped by disease. It's shaped by the drugs used to treat it. Now here’s the headline. Morgan and colleagues found that only about two percent of genus-level microbial clades — six out of two hundred sixty-three — were significantly associated with inflammatory bowel disease status. But twelve percent of analyzed metabolic modules — twenty-four out of two hundred — were differentially abundant. That represents a six-fold gap between compositional and functional signal. That's the study's core argument, quantified. The compositional changes that did emerge tracked with established findings. Firmicutes were depleted, and Enterobacteriaceae were enriched in Crohn's disease, with the Escherichia and Shigella phylotype particularly overabundant in ileal Crohn's. Roseburia and Phascolarctobacterium were significantly reduced in both Crohn's and ulcerative colitis. Faecalibacterium prausnitzii was dramatically reduced in ileal Crohn's. But when the model adjusted for treatment, several of these associations shifted substantially. Mesalamine use was linked to strong reductions in Escherichia and Shigella — changes greater than one hundred percent of average abundance. Antibiotics correlated with losses across multiple genera including Collinsella, Dorea, and Butyricicoccus. Smoking was associated with a decrease of more than sixty percent in Anaerostipes. Strip out those effects, and the disease-specific compositional signal becomes modest. The microbiome you see in a treated inflammatory bowel disease patient reflects both the disease and its treatment, intertwined. That's why function, which proved more consistently perturbed across conditions, tells a clearer story. So what is the inflammatory bowel disease microbiome actually doing differently? Three things stood out. First, oxidative stress pathways were broadly upregulated. Glutathione transport genes increased in both Crohn's and ulcerative colitis. Riboflavin metabolism increased in ileal Crohn's. The pentose phosphate pathway — which generates the nicotinamide adenine dinucleotide phosphate needed to recycle oxidized glutathione back to its active form — was overrepresented in ileal Crohn's. Sulfate transport genes were elevated in both disease subtypes, and metabolism of the sulfur-containing amino acids cysteine and methionine increased, even more so in ileal Crohn's. Morgan and colleagues interpret this cluster as either a shift toward microbes that use mucin — which is rich in cysteine — as a substrate, or as a community-wide response to the reactive oxygen and nitrogen species that flood an inflamed gut. The microbiome, in other words, is adapting to a hostile chemical environment. Second, central biosynthetic capacity collapsed while nutrient scavenging expanded. Genes for synthesizing amino acids — lysine, arginine, and histidine — decreased, while transport modules for importing those same amino acids increased. Cobalamin synthesis, purine and pyrimidine biosynthesis, lipid catabolism, and phospholipid metabolism were all reduced. At the same time, carbohydrate transport genes increased — glucose, hexoses, maltose, mono- and disaccharide transporters — particularly in ileal Crohn's. Short-chain fatty acid production, specifically butanoate and propanoate metabolism, decreased, consistent with the loss of Roseburia and Faecalibacterium. This is the metabolic portrait of a community that has stopped building things and started grabbing what it can find. Morgan and colleagues describe it as a shift toward auxotrophic specialists — microbes that have given up biosynthetic independence in favor of importing nutrients from the host. The cooperative ecology of a healthy gut, where microbes produce short-chain fatty acids that feed intestinal epithelial cells, has been replaced by competition and scavenging. Third, ileal Crohn's disease was specifically marked by increases in virulence and secretion pathways. Genes involved in shigellosis, type two secretion systems, and adherence and invasion processes were overrepresented. The paper notes these functions are associated with the pathobiont adherent-invasive Escherichia coli and may contribute to toxin secretion or elevated cytokine production. The tissue damage that follows would then release metabolites that favor auxotrophic opportunists, which worsens the damage further. The microbiology of ileal Crohn's is not just a more severe version of colonic disease; it has a distinct functional signature. Stepping back, Morgan and colleagues frame the inflammatory bowel disease gut not as a healthy community missing some members, but as an ecologically reorganized system under metabolic stress. The functional perturbations they identified — oxidative stress resilience, nutrient scavenging, collapsed biosynthesis, heightened virulence in the ileum — revolve around what they describe as metabolism in the presence of oxidative stress and perturbed nutrient availability during tissue damage. The compositional losses, like the depletion of Roseburia or Faecalibacterium, are real, but they are part of a larger functional reorganization that taxonomy alone never captured. The study also makes clear that environmental factors and treatments are co-authors of whatever microbiome a clinician observes. Mesalamine, immunosuppressants, antibiotics, and smoking each leave independent marks. Any effort to define what a restored microbiome should look like will need to account for those exposures, not just disease status. Morgan and colleagues call for longitudinal studies, dietary metadata, and integration of transcriptomic, proteomic, and metabolomic data to understand causality. What this study delivers is the first community-wide map of functional disruption in inflammatory bowel disease — a map that shows where the metabolism broke down, even when the roster of species looked almost the same. That shift in perspective, from who to what, is what changes what restoration would even mean. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.